Cargando…
Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies
SIMPLE SUMMARY: Ovarian cancer is often diagnosed only in advanced stages, which limits therapeutic options and prognosis. Therefore, better and easily accessible methods for the early diagnosis of ovarian cancer are needed. In particular, blood-based biomarkers seem to be promising candidates for t...
Autores principales: | Schröder, Lars, Rupp, Alexander B. A., Gihr, Kathrin M. E., Kobilay, Makbule, Domroese, Christian M., Mallmann, Michael R., Holdenrieder, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605106/ https://www.ncbi.nlm.nih.gov/pubmed/37894448 http://dx.doi.org/10.3390/cancers15205081 |
Ejemplares similares
-
Clinical Applicability of Tissue Polypeptide Antigen and CA-125 in Gynecological Malignancies
por: Schröder, Lars, et al.
Publicado: (2023) -
sRAGE alleviates neutrophilic asthma by blocking HMGB1/RAGE signalling in airway dendritic cells
por: Zhang, Fang, et al.
Publicado: (2017) -
Assessment of EN-RAGE, sRAGE and EN-RAGE/sRAGE as potential biomarkers in patients with autoimmune hepatitis
por: Wu, Rui, et al.
Publicado: (2020) -
Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases
por: Pilzweger, Christin, et al.
Publicado: (2015) -
Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD
por: Gopal, Poornima, et al.
Publicado: (2014)